Advancements in the radiooncological treatment of high-risk prostate cancer: a quarter century of achievements

Abstract

The aim of the study was to evaluate the development of treatment of primary high-risk prostate cancer in regards to biochemical no evidence of disease (bNED), acute and late gastrointestinal (GI) and genitourinary (GU) side effects.

Keywords

• biochemical control
• gastrointestinal toxicity
• genitourinary toxicity
• dose escalation